Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Role of Molecular Testing in AML

January 15th 2021

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

January 15th 2021

Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

January 15th 2021

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

January 14th 2021

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.

Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 14th 2021

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

FDA Approves Crizotinib for Pediatric and Young Adult ALK+ Anaplastic Large Cell Lymphoma

January 14th 2021

January 14, 2021 - The FDA has approved crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma.

Immunotherapy Inches Forward in Development of Myeloid Malignancies

January 14th 2021

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

INN Melphalan Flufenamide–DEX for Older Patients With RRMM

January 14th 2021

RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX

January 14th 2021

RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease

January 14th 2021

HORIZON vs MAMMOTH Explored in R/R Multiple Myeloma

January 14th 2021

INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM

January 14th 2021

Treatment Advances in Triple-Class Refractory/Relapsed Myeloma

January 14th 2021

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

January 14th 2021

Emerging Therapies May Offer Fresh Options for TP53-Mutated MDS

January 13th 2021

Two novel treatments options may shake up the landscape for treating patients with myelodysplasia syndrome.

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

January 13th 2021

Prognostic Factors Which Impact ALL Management

January 13th 2021

Dr. DeAngelo on the Utility of Moxetumomab Pasudotox in HCL

January 13th 2021

Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.